Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer

The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and cisplatin activity in non-small-cell lung cancer (NSCLC). Excision repair cross-complementing-1 (ERCC1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5′-nucleotidase (5′-NT), cytidine deaminase (CDA) and ribonucleotide-reductase regulatory subunits (RRM1 and RRM2) were analyzed by quantitative-reverse transcription-PCR in 88 microdissected samples from 69 chemonaive patients. The results showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients. No difference was observed between primary tumor and lymph node metastasis, as well as in adenocarcinoma and squamous-cell carcinoma specimens, while we found a correlation between the CDA-A79C polymorphism and gene expression levels. These data suggest a similar genetic susceptibility to gemcitabine–cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC.

[1]  R. Weinshilboum,et al.  Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics , 2006, Clinical Cancer Research.

[2]  E. Giovannetti,et al.  Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma , 2005, British Journal of Cancer.

[3]  I. Coe,et al.  Differential expression of human nucleoside transporters in normal and tumor tissue. , 2001, Biochemical and biophysical research communications.

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  N. Hanna,et al.  RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer , 2008 .

[6]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Ueda,et al.  The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.

[8]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[10]  Anna Spreafico,et al.  The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  J. Mackey,et al.  cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. , 2005, Lung cancer.

[12]  E. Giovannetti,et al.  Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. , 2009, Pharmacogenomics.

[13]  I. Oh,et al.  Efficacy of Gemcitabine in Patients with Non–Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene , 2008, Clinical Cancer Research.

[14]  Y. Yatabe,et al.  mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines , 2007, Respirology.

[15]  G. Peters,et al.  Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. , 2002, Molecular cancer therapeutics.

[16]  D. Gandara,et al.  Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Kenoki Ohuchida,et al.  Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. , 2008, Anticancer research.

[18]  F. D. De Braud,et al.  Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer , 2003, Pharmacological Reviews.

[19]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[21]  Hyun Cheol Chung,et al.  Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines , 2006, Pharmacogenetics and genomics.

[22]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[23]  E. Felip,et al.  Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery , 2004, Clinical Cancer Research.

[24]  Wang Yang.  DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy , 2010 .

[25]  H. Ueno,et al.  Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Elisa Giovannetti,et al.  Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2005, Molecular Pharmacology.

[27]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[28]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[29]  E. Giovannetti,et al.  Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples , 2008, Nucleosides, nucleotides & nucleic acids.

[30]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[31]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[32]  Dolors Colomer,et al.  Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. , 2006, Haematologica.

[33]  H. Groen,et al.  ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. , 2005, Lung cancer.

[34]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[35]  R. Rosell,et al.  Pharmacogenomics and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  E. Giovannetti,et al.  Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients , 2008, Clinical Cancer Research.

[37]  Y. Yen,et al.  Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. , 1999, Cancer research.

[38]  A. Sancar.  DNA repair in humans. , 1995, Annual review of genetics.

[39]  R. Burgemeister.  New Aspects of Laser Microdissection in Research and Routine , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[40]  G. Peters,et al.  Basis for effective combination cancer chemotherapy with antimetabolites. , 2000, Pharmacology & therapeutics.

[41]  G. Peters,et al.  Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. , 2002, International journal of radiation oncology, biology, physics.

[42]  M. Tsao,et al.  Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. , 1995, Cancer research.

[43]  J. Roh,et al.  An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. , 2007, The oncologist.

[44]  G. Scagliotti,et al.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.

[45]  G. Bepler,et al.  Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.

[46]  S. Seeber,et al.  Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. , 1998, Experimental hematology.

[47]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[48]  Zhong Zheng,et al.  DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. , 2007, The New England journal of medicine.

[49]  Ryuzo Ueda,et al.  Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non‐small cell lung cancer , 2004, Cancer science.